In this Special Edition of the Haymarket Media Coronavirus Briefing, we take a close look at the vaccines, the planned rollout, the obstacles that stand in the way of public acceptance and the educational messaging that will be needed.
November coronavirus death toll reaches nearly 37,000; Canada bans bulk exports of prescription drugs to the U.S.; Trump plans vaccine summit
Ending the pandemic is clearly the top public-health priority for the incoming Biden administration. Will action on drug pricing, ACA reform and data privacy follow?
Moderna requests EUA for vaccine; Amgen, UCB and Takeda partner on COVID trial; FDA ends Unapproved Drugs Initiative.
The latest forecast from WARC calls for a 10.2% drop in global ad spend in 2020, and the organization says it will take until 2022 to recover to 2019’s level of spend.
Three social-media experts – representing in-house, agency and platform – discuss leveraging social media to battle vaccine distrust, harnessing influencers and marketers’ likely use of the medium in 2021.
The venerable health and wellness media brand “skipped a lot of the noise” and thrived during a challenging time for publishers.
The federal government and the private sector will have their work cut out for them encouraging people to get the vaccine, and telling them how to do so.
Regeneron’s experimental coronavirus treatment receives emergency use approval; Pfizer/BioNTech request emergency use approval for COVID-19 vaccine; Vaccine could be distributed as soon as 24-hours after receiving approval.
Pfizer/BioNTech vaccine proves safe and effective; COVID death and hospitalization numbers surge; Biden taps pharma lobbyist for administration.
